Collaboration and Licensing Revenue - Additional Information (Details)													1 Months Ended			3 Months Ended		6 Months Ended
	Mar. 26, 2014 USD ($)	Jan. 10, 2014 USD ($) shares	Dec. 18, 2013 shares	Sep. 30, 2013 USD ($) shares	Jun. 28, 2013 USD ($) shares	Apr. 30, 2013	Mar. 29, 2013 USD ($)	Feb. 14, 2013	Oct. 24, 2012 USD ($) shares	Oct. 05, 2012 USD ($) shares	Jun. 05, 2012 USD ($) shares	Jan. 06, 2011 USD ($) shares	Jun. 30, 2015 USD ($)	May. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)	Jun. 30, 2015 USD ($)	Jun. 30, 2014 USD ($)
Collaboration and Licensing Agreements [Line Items]
Related party payables													$ 57,584,000		$ 214,000	$ 57,584,000		$ 57,584,000
Deferred revenue													180,010,000		113,209,000	180,010,000		180,010,000
Trade, net													141,133,000		14,582,000	141,133,000		141,133,000
Other assets													6,483,000		$ 1,271,000	6,483,000		6,483,000
Collaboration And Licensing Revenue																17,181,000	$ 11,764,000	31,964,000	$ 19,601,000
Ares Trading S.A.
Collaboration and Licensing Agreements [Line Items]
Trade, net													5,000,000			5,000,000		5,000,000
Other assets													5,000,000			5,000,000		5,000,000
Collaborative agreement additional target fee														$ 5,000,000
Maximum milestone payments required upon successful achievement, per product														413,000
Maximum milestone payments required upon successful achievement, one-time														$ 50,000,000
Required notice period for voluntary termination of collaborative agreement														90 days
Collaboration And Licensing Revenue																739,000		$ 739,000
Ares Trading S.A. | ZIOPHARM Oncology, Inc.
Collaboration and Licensing Agreements [Line Items]
Collaboration Arrangement, Percent Of Collaboration Payments																		50.00%
Related party payables													57,500,000			57,500,000		$ 57,500,000
ZIOPHARM Oncology, Inc.
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement												90 days
Collaboration And Licensing Revenue																5,250,000	4,341,000	9,051,000	7,021,000
Percent of shares outstanding at the date of achievement of future milestone												7.495%
Royalty rate as a percentage of net profit												50.00%
Oragenics ECC 1
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement											90 days
Percent of shares outstanding at the date of achievement of future milestone											1.00%
Royalty rate as a percentage of net profit											25.00%
Percentage of shares outstanding at the date of achievement of future milestone 2											1.50%
Percentage of shares outstanding at the date of achievement of future milestone 3											2.00%
Percentage of shares outstanding at the date of achievement of future milestone 4											2.50%
Percentage of shares outstanding at the date of achievement of future milestone 5											3.00%
Oragenics ECC 2
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement				90 days
Consideration to be received upon achievement of future milestone 1																	2,000,000		2,000,000
Consideration to be received upon achievement of future milestone 2																	5,000,000		5,000,000
Consideration to be received upon achievement of future milestone 3																	10,000,000		10,000,000
Royalty rate as a percentage of net sales, tier 1				10.00%
Oragenics ECC 3
Collaboration and Licensing Agreements [Line Items]
Maximum milestone payments required upon successful achievement, per product													22,000
Maximum milestone payments required upon successful achievement, one-time													$ 10,000
Required notice period for voluntary termination of collaborative agreement													90 days
Fibrocell Science, Inc.
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement										90 days
Collaboration And Licensing Revenue																1,918,000	1,331,000	4,079,000	2,641,000
Royalty rate as a percentage of net sales, tier 1										7.00%
Reverse stock split ratio						1-for-25
Reverse stock split, conversion ratio						0.04
Level of net sales at which royalty rate changes to tier 2										$ 25,000,000
Royalty rate as a percentage of net sales, tier 2										14.00%
Royalty rate of savings from improvement										33.00%
Genopaver, LLC
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement							90 days
Collaboration And Licensing Revenue																935,000	491,000	1,604,000	981,000
AquaBounty Technologies, Inc.
Collaboration and Licensing Agreements [Line Items]
Royalty rate as a percentage of gross profit								16.66%
S & I Ophthalmic, LLC
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement				90 days
Collaboration And Licensing Revenue																890,000	607,000	1,645,000	1,486,000
OvaXon, LLC
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement			90 days
Collaboration And Licensing Revenue																662,000	579,000	1,306,000	748,000
Intrexon Energy Partners, LLC
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement	90 days
Collaboration And Licensing Revenue																3,356,000	1,835,000	6,166,000	1,835,000
Persea Bio, LLC
Collaboration and Licensing Agreements [Line Items]
Required notice period for voluntary termination of collaborative agreement															90 days
Collaboration And Licensing Revenue																266,000		506,000
Upfront and Milestone Payments
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													$ 163,094,000		$ 107,228,000	163,094,000		163,094,000
Collaboration And Licensing Revenue																3,703,000	2,517,000	6,734,000	4,399,000
Upfront and Milestone Payments | Ares Trading S.A.
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													56,761,000			56,761,000		56,761,000
Collaboration And Licensing Revenue																739,000		739,000
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc.
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													21,905,000		23,193,000	21,905,000		21,905,000
Collaboration And Licensing Revenue																644,000	644,000	1,288,000	1,288,000
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc. | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value												$ 17,457,000
Collaborative arrangement consideration received, shares | shares												3,636,926
Upfront and Milestone Payments | ZIOPHARM Oncology, Inc. | Milestone One
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value									$ 18,330,000
Collaborative arrangement consideration received, shares | shares									3,636,926
Upfront and Milestone Payments | Ziopharm Oncology ECC Separate Unit of Accounting | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaboration And Licensing Revenue												$ 1,115,000
Upfront and Milestone Payments | Ziopharm Oncology ECC Unit of Accounting One | Upfront
Collaboration and Licensing Agreements [Line Items]
Deferred revenue												$ 16,342,000
Upfront and Milestone Payments | Oragenics ECC 1
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													4,896,000		5,171,000	4,896,000		4,896,000
Upfront and Milestone Payments | Oragenics ECC 1 | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value											$ 6,588,000
Collaborative arrangement consideration received, shares | shares											4,392,425
Upfront and Milestone Payments | Oragenics ECC 2
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													4,591,000		4,839,000	4,591,000		4,591,000
Upfront and Milestone Payments | Oragenics ECC 2 | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value				$ 3,503,000
Collaborative arrangement consideration received, shares | shares				1,348,000
Collaborative arrangement consideration received, value of convertible promissory note				$ 1,956,000
Conversion of promissory note into Common stock | shares			698,241
Upfront and Milestone Payments | Oragenics ECC 3
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													4,954,000			4,954,000		4,954,000
Upfront and Milestone Payments | Oragenics ECC 3 | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value of convertible promissory note													5,000,000
Upfront and Milestone Payments | Fibrocell Science, Inc.
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													16,595,000		17,491,000	16,595,000		16,595,000
Collaboration And Licensing Revenue																448,000	448,000	896,000	896,000
Upfront and Milestone Payments | Fibrocell Science, Inc. | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value										$ 7,576,000
Collaborative arrangement consideration received, shares | shares										1,317,520
Upfront and Milestone Payments | Fibrocell Science, Inc. | Supplemental Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value		$ 5,225,000			$ 7,612,000
Collaborative arrangement consideration received, shares | shares		1,024,590			1,243,781
Upfront and Milestone Payments | Genopaver, LLC
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													2,386,000		2,523,000	2,386,000		2,386,000
Collaboration And Licensing Revenue																68,000	68,000	137,000	137,000
Upfront and Milestone Payments | Genopaver, LLC | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value							$ 3,000,000
Upfront and Milestone Payments | S & I Ophthalmic, LLC
Collaboration and Licensing Agreements [Line Items]
Collaboration And Licensing Revenue																0	0	0	0
Upfront and Milestone Payments | OvaXon, LLC
Collaboration and Licensing Agreements [Line Items]
Collaboration And Licensing Revenue																0	0	0	0
Upfront and Milestone Payments | Intrexon Energy Partners, LLC
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													21,875,000		23,125,000	21,875,000		21,875,000
Collaboration And Licensing Revenue																625,000	$ 625,000	1,250,000	$ 625,000
Upfront and Milestone Payments | Intrexon Energy Partners, LLC | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value	$ 25,000,000
Upfront and Milestone Payments | Persea Bio, LLC
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													4,750,000		5,000,000	4,750,000		4,750,000
Collaboration And Licensing Revenue																125,000		250,000
Upfront and Milestone Payments | Persea Bio, LLC | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value															5,000,000
Prepaid Research and Development Services
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													11,496,000		$ 1,045,000	11,496,000		11,496,000
Prepaid Research and Development Services | Ares Trading S.A.
Collaboration and Licensing Agreements [Line Items]
Deferred revenue													$ 10,000,000			$ 10,000,000		$ 10,000,000
Accounts Receivable [Member] | Upfront and Milestone Payments | Ares Trading S.A. | Upfront
Collaboration and Licensing Agreements [Line Items]
Collaborative arrangement consideration received, value														$ 115,000,000